Raziel Therapeutics Overview
- Founded
- 2012
- Status
- Private
- Latest Deal Type
- Series C
- Latest Deal Amount
- $22.1M
- Investors
- 10
Raziel Therapeutics General Information
Description
Operator of a pharmaceutical firm intended to develop drugs for submental fat, and fat disorders such as Dercum's disease. The company's drug single injection treatment into subcutaneous fat causes immediate fat cell death at the injection site, enabling patients to a significant reduction of fat tissue for long time periods without any invasive procedures.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 10 Prof. Menachem Plaut Street
- Rehovot
- Israel
+972 00-000-0000
Raziel Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 18-Dec-2019 | $22.1M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
| 3. Early Stage VC (Series A) | 25-Feb-2016 | 00.00 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 2. Early Stage VC | 10-Jul-2015 | $1.5M | $2.09M | 00.000 | Completed | Clinical Trials - Phase 1 |
| 1. Early Stage VC | 03-Dec-2012 | $589K | $589K | 00.000 | Completed | Clinical Trials - Phase 1 |
Raziel Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred C | 000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
| Preferred B2 | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
| Preferred B1 | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
| Preferred A2 | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | ||
| Preferred A1 | 25,000 | $16.67 | $16.67 | 1x | $16.67 | 3.08% | ||
| Preferred A | 75,000 | $7.59 | $7.59 | 1x | $7.59 | 4.61% |
Raziel Therapeutics Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Alon Bloomenfeld | Founder, Chief Executive Officer & Board Member |
Raziel Therapeutics Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adi Goldin | Self | Board Member | 000 0000 |
| Alon Bloomenfeld | Raziel Therapeutics | Founder, Chief Executive Officer & Board Member | 000 0000 |
| Eyal Lifschitz | Peregrine Ventures | Board Member | 000 0000 |
| Philippe Schaison | Raziel Therapeutics | Chairman | 000 0000 |
| Shmuel Cabilly Ph.D | Self | Board Member | 000 0000 |
Raziel Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Catalyst Fund | Impact Investing | Minority | 000 0000 | 000000 0 | |
| China Everbright | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Peregrine Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Quark Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Wille Finance | Family Office | Minority | 000 0000 | 000000 0 |